ABUSMEDIUM SIGNALFINANCIAL10-K

ABUS strengthened its balance sheet significantly with a 46% increase in cash to $68.7M and reduced net losses by 21% to -$69.5M, while adding new settlement-related risks with Moderna.

The substantial improvement in financial position suggests successful fundraising or partnership activities that have extended the company's runway for operations. However, the addition of risks related to a "Contingent Settlement Payment" under a Moderna Settlement Agreement introduces new uncertainty that could impact future cash flows and requires monitoring.

Comparing 2026-03-23 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

ABUS demonstrated strong financial improvement across key metrics, with cash and equivalents surging 46% to $68.7M and stockholders' equity increasing 45% to $59.2M, indicating successful capital raising activities. The company also reduced its net losses by 21% to -$69.5M and cut interest expenses by 73%, suggesting improved operational efficiency and reduced debt burden. Overall, the financial picture signals a significantly strengthened balance sheet that should provide greater operational flexibility, though the company remains pre-revenue and continues burning cash.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-89.2%
$1.1M→$117K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Interest Expense
P&L
-73.4%
$1.7M→$459K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+46.1%
$47.0M→$68.7M

Cash position surged 46.1% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+44.7%
$40.9M→$59.2M

Equity base grew 44.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+37.3%
$51.2M→$70.3M

Current assets grew 37.3% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+36.4%
$52.6M→$71.7M

Asset base grew 36.4% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
+21.4%
-$88.4M→-$69.5M

Net income grew 21.4% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+14.3%
$11.0M→$12.5M

Current liabilities rose 14.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-27
ADDED
As of March 18, 2026, the registrant had 195,478,068 common shares, without par value, outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.
We face risks associated with the Contingent Settlement Payment (defined below) under the Moderna Settlement Agreement (defined below).
We do not generate revenues from product sales and may never be profitable from operations.
Several of our clinical trials are currently or were conducted outside the United States, and the FDA may not accept data from trials conducted in locations outside the United States.
+7 more — sign up free →
REMOVED
As of March 25, 2025, the registrant had 191,480,188 common shares, without par value, outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7 A .
Several of our current clinical trials are being conducted outside the United States, and the FDA may not accept data from trials conducted in locations outside the United States.
Current and planned clinical trials may be impacted as a result of the military action by Russia in Ukraine.
We face significant competition from other biotechnology and pharmaceutical companies targeting HBV.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →